bioAffinity Tech Stock Price, News & Analysis

bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has completed its previously announced public offering, raising $4.8 million in gross proceeds. The offering included 1,921,761 shares of Common Stock (or pre-funded warrants) priced at $2.50 per share ($2.493 for pre-funded warrants).

The pre-funded warrants have an exercise price of $0.007 per share and will expire upon full exercise. WallachBeth Capital, LLC served as the sole placement agent for this offering, which was conducted under an effective SEC registration statement on Form S-1.

bioAffinity Technologies (NASDAQ: BIAF, BIAFW), a biotechnology company developing early-stage cancer detection tests, has announced pricing for a $4.8 million public offering. The offering consists of 1,921,799 shares of common stock (or pre-funded warrants) priced at $2.50 per share (or $2.493 per pre-funded warrant).

The pre-funded warrants will have an exercise price of $0.007 per share and will be immediately exercisable until fully exercised. WallachBeth Capital LLC is serving as the sole placement agent, with the offering expected to close around September 30, 2025.

bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has announced pricing for a $4.8 million public offering. The offering consists of 1,921,799 shares of Common Stock (or pre-funded warrants) at $2.50 per share ($2.493 per pre-funded warrant).

The pre-funded warrants will have an exercise price of $0.007 per share and will be immediately exercisable until fully exercised. WallachBeth Capital, LLC is serving as the sole placement agent, with the offering expected to close around September 30, 2025.

bioAffinity Technologies (NASDAQ: BIAF) has released three new case studies demonstrating the clinical effectiveness of its CyPath® Lung noninvasive diagnostic test for lung cancer. The studies showcase how the test aids in critical clinical decision-making, with one case leading to early Stage 1A lung cancer detection and two cases helping avoid unnecessary invasive procedures.

The highlighted cases include: "Samuel," where a positive CyPath® Lung result convinced a hesitant patient to proceed with a biopsy, leading to early cancer detection; "David," where a negative result helped avoid an unnecessary biopsy; and "Lisa," where a positive result supported the decision to proceed with radiation treatment without a risky biopsy in a patient with end-stage COPD.

bioAffinity Technologies (NASDAQ: BIAF) has announced a 1-for-30 reverse stock split effective September 19, 2025. The split was approved by stockholders on July 25, 2025, and aims to bring the company into compliance with Nasdaq's minimum bid price requirement.

Following the split, the company will have approximately 1,338,029 shares outstanding. Stockholders will receive one share for every 30 shares held, with cash payments for fractional shares. Proportionate adjustments will be made to stock options, incentive plans, and outstanding warrants. The company's transfer agent, VStock Transfer LLC, will manage the exchange process.

bioAffinity Technologies (NASDAQ: BIAF) released a case study demonstrating the effectiveness of its CyPath® Lung diagnostic test in identifying lung cancer in a patient with ground-glass pulmonary nodules. The test successfully detected cancer in a 66-year-old former smoker who had multiple ground-glass nodules discovered during an unrelated CT scan.

The case highlights CyPath® Lung's ability to provide actionable results that can expedite treatment decisions, particularly in cases where traditional guidelines recommend 2-5 years of watchful waiting. Following the "likely malignant" test result, robotic bronchoscopy confirmed the cancer diagnosis, leading to immediate surgical treatment referral.

bioAffinity Technologies (NASDAQ:BIAF) received recognition from U.S. Medicine magazine for its CyPath® Lung diagnostic test, highlighting its potential to improve lung cancer detection in veterans while reducing VA healthcare costs. The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting nodules 20mm or smaller.

Research published in the Journal of Health Economics and Outcomes Research revealed potential savings of $895 million for private payers and $379 million for Medicare if CyPath® Lung had been integrated into the standard of care in 2022. The test has successfully detected lung cancer at Stage 1A when other diagnostic tools failed.

bioAffinity Technologies (NASDAQ: BIAF) has strengthened its Board of Directors with two strategic appointments. The company named Roberto Rios, CPA, a veteran financial executive with over 40 years of experience in biotechnology and medical devices, and Dr. John J. Oppenheimer, a distinguished clinical researcher and expert in asthma and COPD treatment.

Dr. Oppenheimer brings extensive clinical expertise with over 180 clinical studies and 260 publications, while Rios contributes significant financial leadership experience from companies including ILEX Oncology and BioMedical Enterprises. These appointments align with bioAffinity's focus on expanding CyPath® Lung sales and developing companion diagnostics for the $26 billion asthma therapeutics market. The company also announced Gary Rubin's departure from the Board for personal reasons.

bioAffinity Technologies (NASDAQ: BIAF) has completed two significant financial transactions totaling approximately $1.2 million in gross proceeds. The company closed a private placement involving 990 shares of Series B Convertible Preferred Stock and warrants to purchase about 6.7 million common stock shares.

Additionally, the company executed a warrant inducement transaction where an existing investor exercised warrants for 1.1 million shares at a reduced exercise price of $0.23 per share (down from $1.50), generating approximately $253,000 in gross proceeds. The investor received new unregistered warrants to purchase 1.4 million shares at $0.352 per share, exercisable upon stockholder approval with a five-year expiration term.